A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.

Trial Profile

A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2014

At a glance

  • Drugs Hemin (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 20 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top